BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND BRD3, KIAA0043, 8019, ENSG00000169925, Q15059, ORFX, RING3L
6 results:

  • 1. BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3.
    Ma L; Wang J; Yang Y; Lu J; Ling J; Chu X; Zhang Z; Tao Y; Li X; Tian Y; Li Z; Zhang Y; Sang X; Lu L; Wan X; Zhang K; Chen Y; Yu J; Zhuo R; Wu S; Pan J; Zhou X; Hu Y; Hu S
    Hematology; 2023 Dec; 28(1):2247253. PubMed ID: 37594294
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.
    Guo J; Liu Y; Lv J; Zou B; Chen Z; Li K; Feng J; Cai Z; Wei L; Liu M; Pang X
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33393503
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma.
    Chan JY; Lim JQ; Yeong J; Ravi V; Guan P; Boot A; Tay TKY; Selvarajan S; Md Nasir ND; Loh JH; Ong CK; Huang D; Tan J; Li Z; Ng CC; Tan TT; Masuzawa M; Sung KW; Farid M; Quek RHH; Tan NC; Teo MCC; Rozen SG; Tan P; Futreal A; Teh BT; Soo KC
    J Clin Invest; 2020 Nov; 130(11):5833-5846. PubMed ID: 33016928
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Targeting BET bromodomain proteins in cancer: The example of lymphomas.
    Spriano F; Stathis A; Bertoni F
    Pharmacol Ther; 2020 Nov; 215():107631. PubMed ID: 32693114
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
    Amorim S; Stathis A; Gleeson M; Iyengar S; Magarotto V; Leleu X; Morschhauser F; Karlin L; Broussais F; Rezai K; Herait P; Kahatt C; Lokiec F; Salles G; Facon T; Palumbo A; Cunningham D; Zucca E; Thieblemont C
    Lancet Haematol; 2016 Apr; 3(4):e196-204. PubMed ID: 27063978
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains.
    Picaud S; Da Costa D; Thanasopoulou A; Filippakopoulos P; Fish PV; Philpott M; Fedorov O; Brennan P; Bunnage ME; Owen DR; Bradner JE; Taniere P; O'Sullivan B; Müller S; Schwaller J; Stankovic T; Knapp S
    Cancer Res; 2013 Jun; 73(11):3336-46. PubMed ID: 23576556
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.